8-K: AngioDynamics Reports Strong Fiscal Year 2025 Results Driven by MedTech Growth and Operational Efficiency

AngioDynamics, Inc. announced robust financial results for its fiscal fourth quarter and full year ended May 31, 2025, showcasing accelerated profitable growth, particularly within its MedTech franchise, and significant strategic advancements.

Summary

• For the fiscal fourth quarter ended May 31, 2025, AngioDynamics reported pro forma net sales of $80.2 million, an increase of 12.7% year-over-year.
• Med Tech net sales in Q4 FY25 grew by 22.0% to $35.8 million, marking the third consecutive quarter of over 20% growth for the franchise.
• Within Med Tech, Auryon sales increased by 19.7% to $15.6 million, and Mechanical Thrombectomy revenue (AngioVac and AlphaVac) surged by 44.7% to $11.3 million.
• NanoKnife disposable sales in Q4 FY25 increased by 5.5% to $5.7 million.
• Med Device net sales for Q4 FY25 were $44.4 million, up 6.2% year-over-year.
• GAAP gross margin for Q4 FY25 was 52.7%, impacted by $1.6 million in tariff-driven Cost of Goods Sold, which represented a 204 basis point headwind.
• Pro forma adjusted EBITDA for Q4 FY25 was $3.4 million, a significant improvement from $1.5 million in the prior-year quarter.
• The company generated $16.2 million of free cash flow in Q4 FY25.
• For the full fiscal year 2025, pro forma net sales reached $292.7 million, an increase of 8.1% compared to the prior year.
• Full-year Med Tech net sales grew 19.5% to $126.7 million, while Med Device net sales increased 0.8% to $166.0 million.
• Full-year GAAP gross margin was 53.9%, inclusive of a 56 basis point tariff headwind.
• Full-year pro forma adjusted EBITDA was $7.6 million, a substantial improvement from a loss of $3.2 million in the prior year.
• The company ended fiscal 2025 with $55.9 million in cash and cash equivalents, exceeding expectations.
• AngioDynamics entered into a revolving credit facility for up to $25.0 million, enhancing financial flexibility, with no capital drawn down as of July 15, 2025.
• The company's portfolio now addresses over $10 billion in annual global market opportunities, up from $3 billion in 2021.

Sentiment

Score: 8

Explanation: The document conveys a highly positive sentiment, emphasizing strong financial performance, significant growth in key MedTech segments, improved profitability, positive free cash flow, and successful strategic repositioning. Management comments are optimistic about future value creation and market opportunities. While tariff impacts are noted, the overall tone and results indicate a company executing well on its strategy.

Positives

• Med Tech franchise achieved its third consecutive quarter of over 20% revenue growth, demonstrating strong market penetration and product adoption.
• Pro forma adjusted EBITDA significantly improved, reaching $3.4 million in Q4 FY25 and $7.6 million for the full fiscal year 2025, indicating enhanced profitability.
• Generated $16.2 million in free cash flow during Q4 FY25, reflecting strong topline growth and operational efficiency.
• Cash balance of $55.9 million at May 31, 2025, was ahead of expectations, providing a strong liquidity position.
• Received CPT Category I Code for Irreversible Electroporation (IRE) for pancreas lesions, effective January 1, 2027, expanding reimbursement pathways for the NanoKnife System.
• Received CPT Category I Code for prostate tissue ablation (effective January 1, 2026) and FDA clearance for prostate tissue ablation (December 2024) for NanoKnife, streamlining reimbursement and expanding its applicability.
• The PRESERVE clinical study for NanoKnife met all primary endpoints, showing 84.0% of patients free from in-field, clinically significant disease at 12 months and strong quality of life outcomes.
• Auryon sales increased by 19.7% in Q4 FY25, with cumulative sales of approximately $185 million since its September 2020 launch and over 130,000 procedures performed globally.
• Mechanical Thrombectomy revenue, including AngioVac and AlphaVac, grew by 44.7% in Q4 FY25, indicating strong demand for these systems.
• Entered into a revolving credit facility for up to $25.0 million, providing enhanced financial flexibility without dilution.
• The company's strategic transformation has repositioned it as a profitable, growth-oriented medical technology company, addressing a significantly larger market opportunity of over $10 billion annually.

Negatives

• GAAP gross margin for Q4 FY25 decreased by 161 basis points to 52.7% compared to the prior-year quarter, primarily due to a $1.6 million tariff impact.
• Med Tech gross margin decreased by 510 basis points to 59.0% in Q4 FY25, primarily related to tariffs, hardware depreciation, and product mix.
• NanoKnife capital sales decreased by 24.9% in Q4 FY25 and 26.0% for the full fiscal year 2025.
• Ports sales within Med Device decreased by 3.5% in Q4 FY25 and 0.7% for the full fiscal year 2025.
• Alatus and Isoloc Balloons sales decreased by 8.5% in Q4 FY25 and 8.7% for the full fiscal year 2025.
• The company incurred a GAAP net loss of $6.1 million in Q4 FY25 and $34.0 million for the full fiscal year 2025.
• Tariff impacts resulted in a $1.6 million cost of goods sold headwind in both Q4 FY25 and for the full fiscal year 2025.

Risks

• The scale and scope of the COVID-19 global pandemic.
• Ability to develop existing and new products.
• Technological advances and patents attained by competitors.
• Infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties.
• Ability to effectively compete against competitors that have substantially greater resources.
• Future actions by the FDA or other regulatory agencies.
• Domestic and foreign health care reforms and government regulations.
• Results of pending or future clinical trials.
• Overall economic conditions, including inflation, tariffs, labor shortages, and supply chain challenges (cost and availability of raw materials).
• Results of ongoing litigation.
• Challenges with respect to third-party distributors or joint venture partners or collaborators.
• Results of sales efforts.
• Effects of product recalls and product liability claims.
• Changes in key personnel.
• Ability to execute on strategic initiatives.
• Effects of economic, credit, and capital market conditions.
• General market conditions.
• Market acceptance of products.
• Foreign currency exchange rate fluctuations.
• Effects on pricing from group purchasing organizations and competition.
• Ability to obtain regulatory clearances or approval of products, or to integrate acquired businesses.

Future Outlook

AngioDynamics provided fiscal year 2026 guidance, projecting net sales between $305 million and $310 million, with Med Tech net sales growth of 12% to 15% and Med Device net sales remaining flat. The company anticipates a gross margin of 53.5% to 55.5% (55.0% to 56.0% absent tariffs) and pro forma adjusted EBITDA between $3.0 million and $8.0 million (or $7.5 million to $10.5 million absent tariffs). Adjusted EPS is expected to be in the range of ($0.35) to ($0.25) (or ($0.30) to ($0.25) absent tariffs), and free cash flow is projected to be positive for the full year FY26 (up to +$5 million absent tariffs). The company expects a $4.0 million to $6.0 million impact from tariffs for FY26.

Management Comments

• Jim Clemmer, President and CEO, stated: "Our strong fourth quarter performance capped off a landmark year at AngioDynamics. We continue to see the positive impacts of our strategic transformation which has enabled us to deliver accelerating topline growth and continued profitability."
• Mr. Clemmer highlighted: "For the third quarter in a row, we posted MedTech growth of over 20% as our unique, innovative platform technologies across both cardiology and interventional oncology continue to take share in highly competitive global markets. That growth, in combination with our operational efficiency efforts, resulted in positive adjusted EBITDA and significant free cash flow despite experiencing some tariff-related headwinds."
• Mr. Clemmer emphasized: "During fiscal 2025, we made significant strides across the organization as we seek to further simplify our business and focus on penetrating large, fast-growing global MedTech markets. Throughout the year, we achieved key regulatory milestones, expanded into new geographies, generated high-quality clinical data, and secured critical reimbursement pathways. The breadth of these accomplishments from NanoKnife's FDA prostate indication and CPT Category I code to AlphaVac's successful commercial launch and Auryon's European expansion reflects our ability to execute across multiple fronts simultaneously."
• Mr. Clemmer concluded: "We've fundamentally repositioned AngioDynamics as a profitable, growth-oriented medical technology company with a portfolio now addressing over $10 billion in annual global market opportunities, up from just $3 billion in 2021. With our proven commercial momentum, multiple growth catalysts, and balance sheet strength, we're exceptionally well-positioned for sustained value creation as we move into fiscal 2026."

Industry Context

AngioDynamics operates within the highly competitive and innovation-driven medical technology sector, specifically focusing on vascular systems, interventional oncology, and cardiology. The company's strategic divestitures of non-core assets and focus on high-growth MedTech platforms like NanoKnife, Auryon, and AlphaVac align with broader industry trends towards specialization and high-value therapeutic areas. The expansion of its addressable market from $3 billion in 2021 to over $10 billion in 2025 demonstrates a successful pivot towards larger, faster-growing segments within the MedTech landscape, positioning it to capture greater market share against competitors.

Comparison to Industry Standards

• No specific comparable companies, projects, or results were mentioned in the document for direct comparison to industry standards.

Legal Proceedings

• Ongoing litigation is listed as a risk factor that may affect actual results.
• Legal expenses related to litigation outside the normal course of business were incurred, including a $19.3 million settlement expense in Q3 FY24 as a result of a settlement agreement with BD.

Stakeholder Impact

• Shareholders: Positive financial results, strategic repositioning, and optimistic future guidance suggest potential for sustained value creation and improved returns.
• Patients: Expansion of cancer treatment options (NanoKnife) and improvements in restoring healthy blood flow (AlphaVac, Auryon) directly benefit patient care and quality of life.
• Healthcare Providers: New CPT codes for NanoKnife procedures are expected to streamline reimbursement, making these innovative treatments more accessible.
• Employees: Operational efficiency efforts and strategic transformation may lead to a more focused and potentially stable work environment, though restructuring and plant closure expenses indicate some past workforce adjustments.
• Creditors/Lenders: Improved financial health, positive cash flow, and a new revolving credit facility enhance the company's creditworthiness and financial flexibility.

Next Steps

• Continue execution of strategies to mitigate potential tariff impacts.
• Ongoing AMBITION BTK RCT and Registry for Auryon.
• Ongoing RECOVER-AV trial for AlphaVac, with first patient enrolled in E.U.
• NanoKnife CPT Category I Code for prostate tissue becomes effective January 1, 2026.
• NanoKnife CPT Category I Code for pancreas lesions becomes effective January 1, 2027.
• Host a conference call on July 15, 2025, at 8:00 am ET to discuss results.

Key Dates

Recommendation

Keywords

Medical Technology, MedTech, Interventional Oncology, Cardiology, Vascular Systems, NanoKnife, Irreversible Electroporation, IRE, Auryon, Peripheral Atherectomy, Thrombus Management, AlphaVac, AngioVac, Mechanical Thrombectomy, CPT Code, FDA Clearance, Financial Results, Earnings, SEC Filing, 8-K, AngioDynamics